ENZON PHARMACEUTICALS, INC. AND SANTARIS PHARMA A/S ENTER INTO GLOBAL COLLABORATION TO DEVELOP NOVEL CANCER THERAPEUTICS

Enzon Pharmaceuticals, Inc. and Santaris Pharma A/S announced that the companies have entered into a collaboration to co-develop and commercialize a series of innovative RNA Antagonists based on Santaris Pharma's LNA (locked nucleic acid) technology and utilizing Enzon's oncology drug development expertise. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=25481&full=1)